Dr. Chris Fraser is a physician specializing in inner-city medicine at Cool Aid’s Community Health Centre in Victoria, BC.

Dr. Fraser has been involved in several CTN studies. He was a co-investigator for CTN 214, which aimed to evaluate the effectiveness of highly active antiretroviral therapy in early HIV infection. He was also a co-investigator for CTN 286: TriiAdd Study, which looked at the effectiveness of a new single-tablet treatment (Triumeq) in achieving viral suppression compared to existing antiretroviral combinations, and for CTN 240 which investigated whether the drug valacyclovir could slow the rate of CD4 cell count decline.